PRECIGEN, INC. (PGEN) Stock
4 of the hedge funds AlphaScala tracks reported PGEN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $7.22M. Company insiders reported 1 open-market buy and 7 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own PGEN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 1.27M | $7.22M | -81% |
| Citadel Ken Griffin | 820K | $4.68M | -70% |
| Renaissance Technologies Jim Simons (founder) | 605K | $3.45M | NEW |
| Millennium Management Israel Englander | 101K | $575.0K | +69% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are PRECIGEN, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 26, 26 | Kindler Jeffrey B | Director | SELL | 185.0K | $1.4M |
| Aug 25, 26 | Tennant Phil | Chief Commercial Officer | SELL | 79.2K | $594K |
| Aug 25, 26 | Shah Rutul R | Chief Operating Officer | SELL | 15.3K | $115K |
| Aug 21, 26 | Shah Rutul R | Chief Operating Officer | SELL | 34.7K | $260K |
| Aug 21, 26 | Agee Nancy H | Director | BUY | 3.4K | $25K |
| Aug 6, 26 | Shah Rutul R | Chief Operating Officer | SELL | 32.7K | $225K |
| Aug 3, 26 | Shah Rutul R | Chief Operating Officer | SELL | 33.8K | $220K |
| Jul 31, 26 | Thomasian Harry Jr. | Chief Financial Officer | SELL | 100.0K | $606K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →PGEN price chart
Powered by TradingViewWhat does PRECIGEN, INC. do?
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company operates through two primary business segments: Biopharmaceuticals and Exemplar. Precigen's therapeutic platforms include the AdenoVerse platform, which leverages a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and UltraCAR-T, which provides chimeric antigen receptor T cell therapies for cancer patients. A significant milestone in the company's development includes FDA approval of PAPZIMEOS (zopapogene imadenovec-drba), the first and only approved therapy for treating adults with recurrent respiratory papillomatosis, a rare and debilitating chronic respiratory disease. Founded in 1998 and headquartered in Germantown, Maryland, Precigen represents an emerging player in the precision medicine sector, combining innovative gene therapy approaches with immunotherapy strategies.